Pretreatment of MDA-MB-231 cells with PODOC1 delays primary tumor development. Growth curves from days 4 to 16 (post-injection) of tumors resulting from subcutaneously injected MDA-MB-231 cells pretreated with isotype control (Iso; red) or one of eight novel candidate antipodocalyxin antibodies (PODOC). (A) PODOC1 Ab (*p < 0.05; n = 3). (B) through (H) Growth curves for other candidate PODOCs (PODOC2 through PODOC8; n = 3). The data shown are representative of two independent experiments.